Logo image of MRNA

MODERNA INC (MRNA) Stock Analyst Earnings Estimates

NASDAQ:MRNA - Nasdaq - US60770K1079 - Common Stock - Currency: USD

35.53  +1.8 (+5.34%)

After market: 35.53 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
Revenue
YoY % growth
MRNA revenue by date.MRNA revenue by date.
19.263B
4.29%
6.848B
-64.45%
3.236B
-52.75%
2.459B
-24.01%
2.985B
21.39%
3.803B
27.40%
5.843B
53.64%
9.098B
55.71%
11.494B
26.34%
9.095B
-20.87%
9.997B
9.92%
EBITDA
YoY % growth
MRNA ebitda by date.MRNA ebitda by date.
9.768B
-27.79%
-1.418B
-114.52%
-3.756B
-164.88%
-3.512B
6.50%
-2.668B
24.03%
-969.911M
63.65%
211.14M
121.77%
1.71B
709.89%
2.973B
73.86%
4.279B
43.93%
5.412B
26.48%
EBIT
YoY % growth
MRNA ebit by date.MRNA ebit by date.
9.42B
-29.15%
-2.039B
-121.65%
-3.945B
-93.48%
-3.843B
2.58%
-2.962B
22.94%
-1.901B
35.82%
-1.257B
33.85%
1.477B
217.46%
3.27B
121.39%
1.651B
-49.51%
2.458B
48.88%
Operating Margin
MRNA operating margin by date.MRNA operating margin by date.
48.90%-29.78%-121.91%-156.30%-99.22%-49.98%-21.52%16.23%28.45%18.15%24.59%
EPS
YoY % growth
MRNA eps by date.MRNA eps by date.
19.96
-29.45%
-12.41
-162.17%
-8.87
28.53%
-9.91
-11.76%
-7.61
23.21%
-5.63
26.03%
-2.18
61.33%
2.87
231.82%
7.10
147.31%
4.83
-31.93%
6.19
28.02%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth
-2.94
4.16%
-2.99
10.14%
-1.44
-4,900.19%
-1.95
22.19%
-2.11
28.24%
-2.22
25.69%
-0.41
71.67%
-0.11
94.23%
Revenue
Q2Q % growth
195.12M
16.84%
171.72M
-28.75%
1.179B
-36.68%
946.44M
-2.02%
146.02M
-25.16%
108.9M
-36.58%
1.259B
6.79%
1.487B
57.12%
EBITDA
Q2Q % growth
-1.326B
-10.50%
-1.36B
-6.89%
-658.798M
-341.32%
-727.862M
31.14%
N/AN/AN/AN/A
EBIT
Q2Q % growth
-1.238B
-0.15%
-1.254B
7.03%
-648.948M
-550.66%
-850.068M
31.78%
-1.118B
9.68%
-1.143B
8.84%
826.2M
227.31%
906.78M
206.67%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2024
Q2Q % growth
-2.50
-554.55%
-2.740.248.71%
Q3 2024
Q2Q % growth
0.03
100.31%
-1.951.98101.54%
Q2 2024
Q2Q % growth
-3.33
8.01%
-3.450.123.51%
Q1 2024
Q2Q % growth
-3.07
-1,715.79%
-3.660.5916.04%
Q4 2023
Q2Q % growth
0.55
-84.76%
-0.991.54155.49%
Q3 2023
Q2Q % growth
-9.53
-476.68%
-1.97-7.56-384.77%
Q2 2023
Q2Q % growth
-3.62
-169.08%
-4.120.5012.15%
Q1 2023
Q2Q % growth
0.19
-97.79%
-1.812.00110.52%
Q4 2022
Q2Q % growth
3.61
-68.02%
4.77-1.16-24.31%
Q3 2022
Q2Q % growth
2.53
-67.14%
3.36-0.83-24.66%
Q2 2022
Q2Q % growth
5.24
-18.89%
4.640.6012.94%
Q1 2022
Q2Q % growth
8.58
202.11%
5.323.2661.43%
Q4 2021
Q2Q % growth
11.29
1,736.23%
10.101.1911.80%
Q3 2021
Q2Q % growth
7.70
1,405.08%
9.23-1.53-16.58%
Q2 2021
Q2Q % growth
6.46
2,183.87%
6.070.396.35%
Q1 2021
Q2Q % growth
2.84
911.43%
2.430.4116.66%
Q4 2020
Q2Q % growth
-0.69
-86.49%
-0.35-0.34-95.61%
Q3 2020
Q2Q % growth
-0.59
-59.46%
-0.43-0.16-35.84%
Q2 2020
Q2Q % growth
-0.31
24.39%
-0.360.0513.37%
Q1 2020
Q2Q % growth
-0.35
12.50%
-0.360.012.79%
Q4 2019
Q2Q % growth
-0.37 -0.430.0613.63%
Q3 2019
Q2Q % growth
-0.37 -0.440.0715.31%
Q2 2019
Q2Q % growth
-0.41 -0.450.048.65%
Q1 2019
Q2Q % growth
-0.40 -0.37-0.03-7.65%
MRNA Yearly EPS VS EstimatesMRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2024
Q2Q % growth
966M
-65.64%
961.7M4.3M0.45%
Q3 2024
Q2Q % growth
1.862B
1.69%
1.275B587M46.04%
Q2 2024
Q2Q % growth
241M
-29.94%
134.83M106.17M78.74%
Q1 2024
Q2Q % growth
167M
-91.03%
99.451M67.549M67.92%
Q4 2023
Q2Q % growth
2.811B
-44.71%
2.545B266M10.45%
Q3 2023
Q2Q % growth
1.831B
-45.57%
1.432B399M27.86%
Q2 2023
Q2Q % growth
344M
-92.76%
326.03M17.97M5.51%
Q1 2023
Q2Q % growth
1.862B
-69.30%
1.202B660M54.91%
Q4 2022
Q2Q % growth
5.084B
-29.50%
5.118B-34M-0.66%
Q3 2022
Q2Q % growth
3.364B
-32.30%
3.597B-233M-6.48%
Q2 2022
Q2Q % growth
4.749B
9.07%
4.147B602M14.52%
Q1 2022
Q2Q % growth
6.066B
213.16%
4.709B1.357B28.82%
Q4 2021
Q2Q % growth
7.211B
1,163.54%
6.928B283M4.08%
Q3 2021
Q2Q % growth
4.969B
3,046.93%
6.331B-1.362B-21.51%
Q2 2021
Q2Q % growth
4.354B
6,457.23%
4.292B62M1.44%
Q1 2021
Q2Q % growth
1.937B
22,959.52%
2.078B-141M-6.79%
Q4 2020
Q2Q % growth
570.7M
3,947.52%
285M285.7M100.25%
Q3 2020
Q2Q % growth
157.9M
828.82%
79.063M78.837M99.71%
Q2 2020
Q2Q % growth
66.4M
406.87%
27.977M38.423M137.34%
Q1 2020
Q2Q % growth
8.4M
-47.50%
17.432M-9.032M-51.81%
Q4 2019
Q2Q % growth
14.1M 17.721M-3.621M-20.43%
Q3 2019
Q2Q % growth
17M 18.725M-1.725M-9.21%
Q2 2019
Q2Q % growth
13.1M 19.176M-6.076M-31.69%
Q1 2019
Q2Q % growth
16M 32.742M-16.742M-51.13%
MRNA Yearly Revenue VS EstimatesMRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS3.82% -14.32% 2.03% 3.36%
Revenue-11.77% -21.37% -2% -1.23%